---
title: Sympathetic Drugs - Adrenergic Pharmacology
type: content
phase: 1
status: complete
priority: high
tags: [sympathetic, adrenergic, agonists, antagonists, alpha-blockers, beta-blockers, catecholamines]
created: 2025-11-08
last_modified: 2025-11-08
---

# Sympathetic Drugs - Adrenergic Pharmacology

## Introduction

Sympathetic drugs, also known as adrenergic drugs, affect the sympathetic nervous system by acting on adrenergic receptors or modulating norepinephrine neurotransmission. These drugs are fundamental to treating cardiovascular, respiratory, and numerous other conditions.

## Adrenergic Receptors

### Receptor Types and Distribution

**α1-Adrenergic Receptors** (Gq → ↑IP3/DAG → ↑Ca2+):
- **Location**: Vascular smooth muscle, prostate, bladder neck, pupillary dilator
- **Effects**: Vasoconstriction, mydriasis, urinary retention, ↑blood pressure

**α2-Adrenergic Receptors** (Gi → ↓cAMP):
- **Location**: Presynaptic nerve terminals (autoreceptors), CNS (locus ceruleus), platelets, vascular smooth muscle
- **Effects**:
  - Presynaptic: ↓NE release (negative feedback)
  - Central: ↓sympathetic outflow, sedation
  - Platelets: Aggregation
  - Postsynaptic vessels: Vasoconstriction (pharmacologic, not physiologic)

**β1-Adrenergic Receptors** (Gs → ↑cAMP → ↑PKA):
- **Location**: Heart, JG cells of kidney
- **Effects**: ↑heart rate (chronotropy), ↑contractility (inotropy), ↑conduction velocity (dromotropy), ↑automaticity, ↑renin release

**β2-Adrenergic Receptors** (Gs → ↑cAMP):
- **Location**: Bronchial smooth muscle, vascular smooth muscle, uterus, liver, skeletal muscle
- **Effects**: Bronchodilation, vasodilation, ↑glycogenolysis, ↑gluconeogenesis, uterine relaxation, tremor, ↓K+ (into cells)

**β3-Adrenergic Receptors** (Gs):
- **Location**: Adipose tissue, bladder
- **Effects**: Lipolysis, bladder relaxation

### Receptor Selectivity Mnemonic

- **β1**: "1 heart" - primarily cardiac
- **β2**: "2 lungs" - primarily pulmonary
- **α1**: Vasoconstriction, mydriasis, urinary retention
- **α2**: Presynaptic inhibition, CNS effects

---

## Sympathomimetics (Adrenergic Agonists)

### Classification

**By Mechanism**:
1. **Direct-acting**: Bind and activate adrenergic receptors
2. **Indirect-acting**: ↑NE release or ↓NE reuptake/metabolism
3. **Mixed-acting**: Both direct and indirect

**By Selectivity**:
1. Non-selective (α and β)
2. α-selective (α1 or α2)
3. β-selective (β1 or β2)
4. Mixed α/β

### Catecholamines

**Structure**: Catechol ring (3,4-dihydroxybenzene) + ethylamine side chain

**Characteristics**:
- High potency
- Rapid onset, short duration (minutes)
- Poor oral bioavailability (first-pass by COMT, MAO)
- Cannot cross BBB (polar)
- IV administration required

**Metabolism**:
- **COMT** (Catechol-O-Methyltransferase): Major pathway
- **MAO** (Monoamine Oxidase): MAO-A (NE, 5-HT), MAO-B (dopamine)

#### Epinephrine (Adrenaline)

**Receptor Activity**: β1 = β2 > α1 (dose-dependent)
- Low doses: β effects predominate (β2 vasodilation)
- High doses: α effects add (vasoconstriction)

**Pharmacokinetics**:
- IV, IM, SC, inhalation, topical (NOT oral)
- Onset: IV immediate, IM 5-10 min, SC 6-15 min
- Duration: 5-10 minutes
- Metabolism: COMT, MAO → metanephrine, VMA

**Pharmacodynamics**:

**Cardiovascular**:
- ↑HR (β1): Positive chronotropy
- ↑Contractility (β1): Positive inotropy
- ↑Cardiac output
- Vasoconstriction (α1) in skin, mucosa, kidneys
- Vasodilation (β2) in skeletal muscle, liver
- **Net effect on BP**: ↑systolic BP, ↓or unchanged diastolic BP (β2 vasodilation), ↑pulse pressure

**Respiratory**:
- Powerful bronchodilation (β2)
- ↓Mediator release from mast cells

**Metabolic**:
- ↑Glycogenolysis (β2, α1)
- ↑Gluconeogenesis
- ↑Lipolysis (β1, β3)
- ↑Blood glucose
- ↑Lactate
- Hypokalemia (β2 → K+ into cells)

**Other**:
- Mydriasis (α1)
- ↓GI motility (α, β)
- Uterine relaxation (β2)

**Clinical Uses**:
1. **Anaphylaxis** (drug of choice): IM 0.3-0.5 mg (1:1000)
   - Bronchodilation, vasoconstriction, ↓mediator release
2. **Cardiac arrest**: IV/IO 1 mg q3-5min
3. **Severe acute asthma**: SC (rarely used now)
4. **Adjunct to local anesthetics**: Vasoconstriction → ↑duration, ↓systemic absorption
5. **Glaucoma**: Topical (↓aqueous humor production)

**Adverse Effects**:
- Anxiety, tremor, headache
- Palpitations, tachycardia, arrhythmias
- Hypertension, cerebral hemorrhage (high doses)
- Pulmonary edema (α1-mediated)
- Hyperglycemia, hypokalemia
- Tissue necrosis if extravasation (α1 vasoconstriction)

**Contraindications**:
- Patients on non-selective β-blockers (unopposed α → severe HTN)
- Angle-closure glaucoma (if systemic)
- During general anesthesia with halogenated hydrocarbons (arrhythmias)

**Antidote**: Phentolamine (α-blocker) for extravasation

#### Norepinephrine (Noradrenaline)

**Receptor Activity**: α1 = α2 > β1 >> β2 (minimal β2)

**Pharmacokinetics**: Similar to epinephrine (IV only)

**Pharmacodynamics**:

**Cardiovascular**:
- Potent vasoconstriction (α1) → ↑peripheral resistance
- ↑Systolic and diastolic BP
- **Reflex bradycardia** (baroreceptor response to ↑BP)
  - ↑BP → baroreceptors → vagal activation → ↓HR
  - Counteracts direct β1 effect
- ↑Contractility (β1) but cardiac output often unchanged or decreased
- Coronary blood flow may increase (↑perfusion pressure)

**Clinical Uses**:
1. **Septic shock**: Vasopressor of choice
2. **Neurogenic shock**
3. **Cardiogenic shock** (with dobutamine)
4. **Hypotension** refractory to other agents

**Adverse Effects**:
- Severe hypertension
- Bradycardia (reflex)
- Tissue necrosis with extravasation
- Organ ischemia (renal, mesenteric)
- Arrhythmias

**Administration**:
- Central line preferred
- Continuous infusion (titrate to MAP >65)
- Monitor closely

**Antidote**: Phentolamine for extravasation

#### Isoproterenol

**Receptor Activity**: β1 = β2 >> α (pure β-agonist)

**Pharmacodynamics**:

**Cardiovascular**:
- ↑HR (β1): Marked tachycardia
- ↑Contractility (β1)
- ↑Cardiac output (significantly)
- Vasodilation (β2) → ↓peripheral resistance
- **Net effect**: ↑systolic BP, ↓diastolic BP, ↓mean arterial pressure

**Respiratory**:
- Bronchodilation (β2)

**Clinical Uses**:
1. **Bradyarrhythmias** (AV block, bradycardia): Temporary until pacing
2. **Torsades de pointes**: ↑HR shortens QT
3. Rarely: Shock (historical)

**Adverse Effects**:
- Severe tachycardia, palpitations
- Arrhythmias (increased automaticity)
- Hypotension (β2 vasodilation)
- Myocardial ischemia (↑O2 demand, ↓diastolic perfusion)

**Largely replaced** by: Pacing, atropine, epinephrine

#### Dopamine

**Receptor Activity**: Dose-dependent
- **Low dose (2-5 mcg/kg/min)**: D1 > β1 > α1
  - D1: Renal and mesenteric vasodilation
- **Medium dose (5-10 mcg/kg/min)**: β1 > D1 > α1
  - ↑Cardiac contractility and output
- **High dose (>10 mcg/kg/min)**: α1 > β1 > D1
  - Vasoconstriction (like norepinephrine)

**Pharmacokinetics**:
- IV infusion only
- Metabolized by MAO, COMT
- Duration: <5 minutes

**Clinical Uses**:
1. **Cardiogenic shock**
2. **Septic shock** (controversial; NE preferred)
3. **Bradycardia with hypotension**

**Adverse Effects**:
- Tachycardia, arrhythmias
- Hypertension (high doses)
- Nausea, vomiting (D2 in CTZ)
- Tissue necrosis if extravasation
- May worsen pulmonary shunting

**Notes**:
- "Renal-dose dopamine" (2-5 mcg/kg/min) controversial; not shown to prevent AKI
- Extravasation: Treat with phentolamine

#### Dobutamine

**Receptor Activity**: β1 > β2 >> α1

**Pharmacodynamics**:
- ↑Contractility (β1): Positive inotrope
- Minimal effect on HR (less than isoproterenol)
- Vasodilation (β2) → ↓afterload
- ↑Cardiac output, ↓PCWP
- Usually ↓or unchanged BP

**Clinical Uses**:
1. **Acute decompensated heart failure**
2. **Cardiogenic shock**
3. **Stress echocardiography** (pharmacologic stress testing)
4. **Bridge to transplant** (chronic infusions)

**Adverse Effects**:
- Tachycardia (less than isoproterenol)
- Arrhythmias
- Hypotension (β2 vasodilation)
- Tolerance with prolonged use
- ↑Myocardial O2 demand

**Contraindications**:
- HOCM (hypertrophic obstructive cardiomyopathy)
- Severe aortic stenosis

---

### Selective α-Agonists

#### Phenylephrine

**Receptor Activity**: α1 >> α2 (selective α1-agonist)

**Pharmacokinetics**:
- Not a catecholamine (no catechol ring)
- Oral, IV, topical
- Resistant to COMT (longer duration than catecholamines)
- Duration: 5-20 minutes (IV), hours (oral)

**Pharmacodynamics**:
- Pure vasoconstriction (α1)
- ↑Peripheral resistance
- ↑Systolic and diastolic BP
- **Reflex bradycardia** (baroreceptor-mediated)
- ↓Cardiac output (↑afterload + bradycardia)

**Clinical Uses**:
1. **Hypotension**: Surgical, neuraxial anesthesia
2. **Nasal decongestant**: Topical, oral (Sudafed PE)
3. **Mydriasis**: Ophthalmology (pupil dilation)
4. **Supraventricular tachycardia**: Vagal stimulation via baroreceptor reflex (rarely used)

**Adverse Effects**:
- Reflex bradycardia
- Hypertension
- Tissue necrosis (extravasation)
- Rebound congestion (nasal)

**Notes**:
- Useful when pure vasoconstriction needed (e.g., spinal anesthesia hypotension)
- Less arrhythmogenic than epinephrine

#### Midodrine

**Receptor Activity**: Prodrug → desglymidodrine (α1-agonist)

**Clinical Uses**:
1. **Orthostatic hypotension**
2. **Neurogenic orthostatic hypotension**

**Adverse Effects**: Supine hypertension, pilomotor reactions, urinary retention

#### Oxymetazoline, Xylometazoline

**Receptor Activity**: α1, α2

**Clinical Uses**: **Nasal decongestants** (topical)

**Adverse Effects**:
- Rebound congestion (rhinitis medicamentosa) after 3-5 days
- Avoid prolonged use (>3 days)

---

### Selective α2-Agonists

#### Clonidine

**Receptor Activity**: α2 >> α1 (central and peripheral α2-agonist)

**Mechanism**:
- **Central α2 activation** (locus ceruleus, medulla)
  - ↓Sympathetic outflow
  - ↑Vagal tone
- Presynaptic α2: ↓NE release

**Pharmacokinetics**:
- Oral, transdermal patch, epidural
- Well absorbed orally
- Half-life: 12-16 hours
- Renal excretion

**Pharmacodynamics**:
- ↓Sympathetic tone → ↓BP, ↓HR
- Sedation (CNS α2)
- Dry mouth (↓salivation)

**Clinical Uses**:
1. **Hypertension** (second-line)
2. **ADHD** (adjunct, especially with tics)
3. **Opioid/alcohol withdrawal** (↓sympathetic symptoms)
4. **Tourette syndrome**
5. **Menopausal hot flashes**
6. **Epidural analgesia** (adjunct)

**Adverse Effects**:
- Sedation, drowsiness
- Dry mouth
- Bradycardia
- **Rebound hypertension** if stopped abruptly (↑sympathetic surge)
  - Must taper over 2-4 days
- Depression
- Constipation

**Contraindications**: Sick sinus syndrome, severe bradycardia

**Drug Interactions**:
- TCAs may antagonize antihypertensive effect
- β-blockers + clonidine withdrawal → severe hypertensive crisis

#### Methyldopa

**Mechanism**:
- Prodrug → α-methylnorepinephrine (false neurotransmitter)
- α-Methylnorepinephrine activates central α2 receptors
- ↓Sympathetic outflow

**Pharmacokinetics**:
- Oral, IV
- Crosses BBB
- Half-life: 2 hours

**Clinical Uses**:
1. **Hypertension in pregnancy** (safe, preferred)
2. Hypertension (second-line)

**Adverse Effects**:
- Sedation, drowsiness
- Positive Coombs test (10-20%), hemolytic anemia (rare)
- Hepatotoxicity (rare but serious)
- Dry mouth
- Sexual dysfunction
- Rebound hypertension (less severe than clonidine)

**Safety in Pregnancy**: Category B; drug of choice for chronic HTN in pregnancy

#### Dexmedetomidine

**Receptor Activity**: Selective α2-agonist

**Clinical Uses**:
1. **ICU sedation** (mechanically ventilated patients)
2. **Procedural sedation**
3. **Adjunct in anesthesia**

**Advantages**:
- "Cooperative sedation" (arousable)
- No respiratory depression
- Analgesia
- ↓Delirium

**Adverse Effects**:
- Bradycardia, hypotension
- Initial transient hypertension (peripheral α2)

---

### Selective β-Agonists

#### β1-Selective Agonists

**Dobutamine**: See above under catecholamines

#### β2-Selective Agonists

**Short-Acting β2-Agonists (SABAs)**:

**Albuterol (Salbutamol)**:

**Receptor Activity**: β2 > β1 (15:1 selectivity)

**Pharmacokinetics**:
- Inhalation (MDI, nebulizer), oral, IV
- Onset: 5-15 minutes (inhaled)
- Duration: 4-6 hours
- Oral bioavailability low

**Pharmacodynamics**:
- Bronchodilation (β2)
- ↓Mast cell mediator release
- Mild tachycardia (β1, reflex)
- Tremor (β2 in skeletal muscle)
- Hypokalemia (β2 → K+ into cells)

**Clinical Uses**:
1. **Acute asthma exacerbation** (rescue inhaler)
2. **COPD exacerbation**
3. **Hyperkalemia** (off-label; shifts K+ intracellularly)
4. **Tocolysis** (off-label; delays preterm labor)

**Adverse Effects**:
- Tremor (most common)
- Tachycardia, palpitations
- Headache
- Hypokalemia (high doses)
- Hyperglycemia
- Paradoxical bronchospasm (rare)

**Similar Drugs**: Levalbuterol (R-enantiomer of albuterol), metaproterenol, pirbuterol

**Long-Acting β2-Agonists (LABAs)**:

**Salmeterol, Formoterol**:

**Pharmacokinetics**:
- Inhalation only
- Duration: 12 hours

**Clinical Uses**:
1. **Chronic asthma maintenance** (ALWAYS with inhaled corticosteroid)
2. **COPD maintenance**

**Black Box Warning**:
- **Increased asthma-related deaths** when used as monotherapy
- **MUST use with inhaled corticosteroid** in asthma
- Often combined in single inhaler (Advair = fluticasone/salmeterol)

**Adverse Effects**: Similar to SABAs but less frequent

**Ultra-Long-Acting**:
- **Indacaterol, vilanterol, olodaterol**: 24-hour duration

#### Terbutaline

**Receptor Activity**: β2-selective

**Clinical Uses**:
1. **Asthma/COPD**: Less common now
2. **Tocolysis** (preterm labor): FDA warning against prolonged use (maternal cardiac events)

**Route**: SC, oral, inhaled

---

### Mixed and Indirect-Acting Sympathomimetics

#### Ephedrine

**Mechanism**: Mixed direct (α, β) and indirect (↑NE release)

**Pharmacokinetics**:
- Oral, IV, IM
- Crosses BBB
- Not metabolized by COMT/MAO
- Longer duration than catecholamines

**Pharmacodynamics**:
- Bronchodilation
- ↑BP, ↑HR
- CNS stimulation
- Mydriasis

**Clinical Uses**:
1. **Hypotension** (especially anesthesia-related)
2. **Nasal decongestant** (historical)
3. Precursor to methamphetamine (restricted)

**Adverse Effects**:
- Tachycardia, palpitations
- Hypertension
- Insomnia, anxiety
- Tachyphylaxis (depletes NE stores)
- Urinary retention

**Contraindicated** with MAOIs (hypertensive crisis)

#### Pseudoephedrine

**Mechanism**: Mixed (like ephedrine but less CNS penetration)

**Clinical Uses**: **Nasal decongestant** (oral)

**Adverse Effects**: Less CNS stimulation than ephedrine

**Note**: Behind-the-counter due to methamphetamine synthesis potential

#### Amphetamine, Methamphetamine

**Mechanism**:
- Indirect: ↑NE and dopamine release, ↓reuptake
- Crosses BBB readily

**Clinical Uses**:
- **ADHD**: Amphetamine salts (Adderall), lisdexamfetamine (Vyvanse)
- **Narcolepsy**
- Methamphetamine: Limited (Desoxyn) - severe ADHD

**Adverse Effects**:
- Insomnia, anorexia
- Tachycardia, hypertension
- Psychosis (high doses)
- Addiction potential

**Contraindicated** with MAOIs

#### Cocaine

**Mechanism**:
- Blocks NE, dopamine, serotonin reuptake (indirect)
- Local anesthetic (blocks Na+ channels)

**Pharmacodynamics**:
- Euphoria (dopamine in nucleus accumbens)
- Sympathomimetic effects (α, β)
- Vasoconstriction

**Clinical Uses**:
- **Topical anesthesia**: Nose, throat (ENT procedures)
  - Only local anesthetic with intrinsic vasoconstrictor properties

**Toxicity**:
- Myocardial infarction (vasoconstriction + ↑demand)
- Stroke, seizures
- Hyperthermia
- Arrhythmias
- Aortic dissection

**Treatment**:
- Benzodiazepines (first-line for agitation, HTN, seizures)
- **Avoid β-blockers** (unopposed α → worse vasoconstriction)
- Nitroglycerin or CCBs for coronary vasospasm

#### Tyramine

**Mechanism**: Indirect (↑NE release from vesicles)

**Source**: Aged cheeses, cured meats, fermented foods

**Clinical Significance**:
- **Tyramine reaction with MAOIs** → hypertensive crisis
- Normally metabolized by MAO in gut/liver
- MAOIs prevent metabolism → ↑systemic tyramine → NE release

---

## Sympatholytics (Adrenergic Antagonists)

### α-Blockers

#### Non-Selective α-Blockers

**Phentolamine**:

**Receptor Activity**: Competitive α1 and α2 antagonist

**Pharmacokinetics**:
- IV, IM
- Short duration (minutes)

**Clinical Uses**:
1. **Pheochromocytoma diagnosis** (historical; biochemical tests now)
2. **Hypertensive crisis** from pheochromocytoma
3. **Catecholamine extravasation** (antidote - local injection)
4. **Cocaine-induced MI** (with nitroglycerin/CCB)
5. **Clonidine withdrawal hypertension**

**Adverse Effects**:
- Hypotension, reflex tachycardia (loss of α2 presynaptic inhibition → ↑NE → β1)
- Arrhythmias
- GI stimulation

**Phenoxybenzamine**:

**Receptor Activity**: Irreversible (covalent) α1 and α2 antagonist

**Pharmacokinetics**:
- Oral
- Long duration (days - irreversible binding)

**Clinical Uses**:
1. **Pheochromocytoma** preoperative preparation (gold standard)
   - Start 7-14 days before surgery
   - Prevents intraoperative HTN crisis
2. **Benign prostatic hyperplasia** (rarely used)

**Adverse Effects**:
- Orthostatic hypotension
- Reflex tachycardia (give β-blocker AFTER α-blockade established)
- Nasal congestion
- Miosis

**Note**: Always α-blockade before β-blockade in pheochromocytoma (otherwise unopposed α)

#### Selective α1-Blockers

**Prazosin, Doxazosin, Terazosin** ("-zosin"):

**Receptor Activity**: Selective competitive α1 antagonists

**Pharmacokinetics**:
- Oral
- Prazosin: Short-acting (t½ 2-3h), BID-TID dosing
- Doxazosin, terazosin: Longer-acting, QD dosing
- Hepatic metabolism

**Pharmacodynamics**:
- Vasodilation (arterial and venous)
- ↓Peripheral resistance → ↓BP
- No reflex tachycardia (α2 intact → presynaptic inhibition maintained)
- Prostate/bladder neck relaxation

**Clinical Uses**:
1. **Hypertension** (second-line, less preferred than thiazides, ACE-I, CCB)
2. **Benign prostatic hyperplasia (BPH)**
3. **PTSD-related nightmares** (prazosin - off-label)
4. **Raynaud phenomenon** (vasodilation)

**Adverse Effects**:
- **First-dose orthostatic hypotension** (common, especially prazosin)
  - Dose at bedtime, start low
  - Warn patient to sit/lie down if dizzy
- Dizziness, lightheadedness
- Headache
- Nasal congestion
- Peripheral edema (vasodilation)
- Sexual dysfunction (less than β-blockers)

**Uroselective α1A-Blockers**:

**Tamsulosin, Alfuzosin, Silodosin**:

**Receptor Activity**: α1A-selective (prostate, bladder neck > vasculature)

**Advantages**:
- Less orthostatic hypotension (more selective for urinary tract)
- Preferred for BPH

**Clinical Uses**: **BPH** (first-line)

**Adverse Effects**:
- Orthostatic hypotension (less than non-selective)
- **Abnormal ejaculation** (retrograde) - especially silodosin
- Dizziness
- **Intraoperative floppy iris syndrome** (during cataract surgery)
  - Inform ophthalmologist if on α-blocker

**Phentolamine**: See non-selective α-blockers above

---

### β-Blockers (β-Adrenergic Antagonists)

**Classification**:

1. **By Selectivity**:
   - Non-selective: β1 = β2
   - β1-selective (cardioselective): β1 > β2

2. **By Intrinsic Sympathomimetic Activity (ISA)**:
   - With ISA: Partial agonist activity
   - Without ISA: Pure antagonists

3. **By Additional Properties**:
   - α-blocking activity
   - Membrane-stabilizing activity (local anesthetic)

#### Non-Selective β-Blockers

**Propranolol**:

**Receptor Activity**: β1 = β2 antagonist (non-selective)

**Pharmacokinetics**:
- Oral, IV
- Lipophilic → crosses BBB
- High first-pass metabolism (oral bioavailability ~25%)
- Hepatic metabolism (CYP2D6)
- Half-life: 3-6 hours
- IR and ER formulations

**Pharmacodynamics**:

**Cardiovascular (β1 blockade)**:
- ↓HR, ↓contractility
- ↓Cardiac output
- ↓BP (multiple mechanisms)
- ↓Renin release
- ↑Peripheral resistance initially (unopposed α)

**Respiratory (β2 blockade)**:
- Bronchoconstriction

**Metabolic (β2 blockade)**:
- Inhibits glycogenolysis
- Masks hypoglycemia symptoms
- ↑Triglycerides, ↓HDL (transient)

**Other**:
- CNS: Crosses BBB → sedation, nightmares
- Membrane-stabilizing effect (high doses)

**Clinical Uses**:
1. **Hypertension**
2. **Angina pectoris** (↓O2 demand)
3. **Post-MI** (↓mortality)
4. **Heart failure** (chronic, stable)
5. **Arrhythmias**: SVT, atrial fibrillation (rate control)
6. **Hyperthyroidism** (symptom control - β-mediated symptoms)
7. **Migraine prophylaxis**
8. **Essential tremor**
9. **Portal hypertension** (↓bleeding from varices)
10. **Performance anxiety** (stage fright)
11. **Hypertrophic cardiomyopathy**
12. **Pheochromocytoma** (AFTER α-blockade)
13. **Thyroid storm**
14. **Akathisia** (antipsychotic side effect)

**Adverse Effects**:
- Bradycardia, AV block
- **Bronchospasm** (β2 blockade - avoid in asthma/COPD)
- Hypotension
- Fatigue, depression
- Sexual dysfunction
- Impaired exercise tolerance
- Masks hypoglycemia (blocks tachycardia, tremor; sweating intact)
- Hypertriglyceridemia
- Cold extremities
- CNS: Nightmares, insomnia, depression (lipophilic)

**Contraindications**:
- Asthma, severe COPD (β2 blockade)
- Decompensated heart failure
- Bradycardia, heart block (2nd/3rd degree)
- Sick sinus syndrome
- Severe peripheral vascular disease
- Prinzmetal angina (coronary vasospasm)
- Cocaine use (unopposed α → worse vasoconstriction)

**Drug Interactions**:
- Verapamil/diltiazem: Additive AV block, bradycardia
- Clonidine: Severe rebound hypertension if β-blocker stopped first

**Withdrawal**: Gradual taper over 1-2 weeks (receptor upregulation → rebound tachycardia, HTN, angina, MI)

**Nadolol**:
- Non-selective
- Hydrophilic (doesn't cross BBB)
- Renal excretion
- Long half-life (QD dosing)
- Less CNS side effects

**Timolol**:
- Non-selective
- **Topical ophthalmic** for glaucoma
- Can cause systemic β-blockade (especially in children)

**Sotalol**:
- Non-selective β-blocker + Class III antiarrhythmic (K+ channel blocker)
- Prolongs QT interval
- Used for atrial fibrillation, ventricular arrhythmias
- Risk of torsades de pointes

**Pindolol, Acebutolol**:
- Partial agonist activity (ISA)
- Less bradycardia, less ↓cardiac output
- May be better tolerated
- Less benefit post-MI

#### β1-Selective (Cardioselective) β-Blockers

**Metoprolol**:

**Receptor Activity**: β1 > β2 (cardioselective, ~20:1 at low doses)

**Pharmacokinetics**:
- Oral, IV
- Lipophilic
- Hepatic metabolism (CYP2D6)
- Tartrate (IR, BID-TID) vs. succinate (ER, QD)
- Half-life: 3-7 hours

**Advantages over non-selective**:
- Safer in COPD, peripheral vascular disease (at low doses)
- **Still avoid in asthma** (selectivity lost at higher doses)
- Less metabolic effects

**Clinical Uses**: Similar to propranolol
- Hypertension, angina, post-MI, heart failure

**Adverse Effects**: Similar to propranolol but less bronchospasm

**Atenolol**:
- β1-selective
- **Hydrophilic** (doesn't cross BBB)
- Renal excretion
- Long half-life (QD dosing)
- Fewer CNS side effects

**Bisoprolol**:
- β1-selective
- QD dosing
- Preferred for heart failure (CIBIS-II trial)

**Esmolol**:
- β1-selective
- **Ultra-short acting** (t½ 9 minutes)
- IV only
- Metabolized by RBC esterases
- Used for acute/urgent situations:
  - Intraoperative hypertension/tachycardia
  - Acute MI
  - Thyroid storm
  - Aortic dissection
- Easily titratable, rapidly reversible

**Nebivolol**:
- β1-selective
- **Vasodilatory** (↑NO production)
- May have advantages in heart failure
- Less sexual dysfunction

#### Mixed α/β-Blockers

**Labetalol**:

**Receptor Activity**: β (β1 = β2) and α1 antagonist (ratio β:α = 3:1 oral, 7:1 IV)

**Pharmacokinetics**:
- Oral, IV
- First-pass metabolism

**Pharmacodynamics**:
- ↓BP (α1 blockade)
- ↓HR, ↓contractility (β blockade)
- No reflex tachycardia (α blockade)

**Clinical Uses**:
1. **Hypertensive emergency** (IV)
2. **Hypertension in pregnancy** (safe, preferred with methyldopa)
3. **Pheochromocytoma** (after or with α-blockade)
4. **Clonidine withdrawal**

**Adverse Effects**:
- Orthostatic hypotension (α1 blockade)
- Bronchospasm (β2 blockade - avoid in asthma)
- Hepatotoxicity (rare)

**Carvedilol**:

**Receptor Activity**: β (β1 = β2) and α1 antagonist

**Additional Properties**:
- **Antioxidant**
- **Anti-proliferative**

**Clinical Uses**:
1. **Heart failure** (↓mortality; COPERNICUS trial)
2. **Hypertension**
3. **Post-MI**

**Pharmacokinetics**:
- Oral, BID dosing
- Hepatic metabolism

**Adverse Effects**: Similar to labetalol

**Special Note**: Superior to metoprolol for heart failure mortality reduction

---

## Clinical Pearls

1. **Epinephrine is drug of choice for anaphylaxis**: IM administration
2. **Norepinephrine is vasopressor of choice for septic shock**
3. **Never use β-blockers with cocaine**: Unopposed α → severe HTN, vasoconstriction
4. **Always α-blockade before β-blockade in pheochromocytoma**: Prevent hypertensive crisis
5. **β-blockers mask hypoglycemia symptoms**: Caution in diabetics on insulin
6. **Non-selective β-blockers contraindicated in asthma**: β2 blockade → bronchoconstriction
7. **Taper β-blockers gradually**: Prevent rebound (upregulated receptors)
8. **Reflex bradycardia**: NE, phenylephrine (pure α-agonists)
9. **First-dose hypotension**: α1-blockers (prazosin)
10. **SABAs for acute asthma, LABAs for maintenance** (with ICS)
11. **Dobutamine for acute heart failure**: Inotrope with ↓afterload
12. **Clonidine rebound hypertension**: Taper over 2-4 days
13. **Tamsulosin for BPH**: Less hypotension than prazosin
14. **Propranolol for thyroid storm**: Blocks peripheral conversion T4→T3

---

## Key Takeaways

1. **Adrenergic receptors**: α1 (vasoconstriction), α2 (presynaptic inhibition, CNS), β1 (heart), β2 (lungs, vessels)
2. **Catecholamines**: Short-acting, IV only, metabolized by COMT/MAO
3. **Epinephrine**: Anaphylaxis, cardiac arrest
4. **Norepinephrine**: Septic shock (vasoconstriction)
5. **Dobutamine**: Acute heart failure (inotrope)
6. **Phenylephrine**: Pure α1 (vasoconstriction, reflex bradycardia)
7. **Clonidine**: Central α2 (↓sympathetic outflow, rebound HTN risk)
8. **Albuterol**: β2-agonist (bronchodilation, rescue inhaler)
9. **α1-blockers**: BPH (tamsulosin), HTN (doxazosin), first-dose hypotension
10. **β-blockers**: HTN, angina, post-MI, HF, arrhythmias; contraindicated in asthma
11. **Cardioselective β-blockers**: Metoprolol, atenolol (safer in COPD)
12. **Mixed α/β-blockers**: Labetalol (HTN emergency, pregnancy), carvedilol (HF)

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
3. Rang & Dale's Pharmacology, 9th Edition
4. ACC/AHA Heart Failure Guidelines
5. GINA Guidelines for Asthma Management
